New guidelines for managing pulmonary hypertension: what the pediatrician needs to know

Steven H Abman1

  • 1Pediatric Heart Lung Center, Section of Pediatric Pulmonary Medicine, Department of Pediatrics, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.

Insights

New guidelines offer expert recommendations for diagnosing and evaluating pediatric pulmonary hypertension, a serious condition affecting children with various diseases. Further research is crucial for improving long-term outcomes in these young patients.

Area of Science:

  • Pediatric pulmonology and cardiology
  • Vascular disease in children
  • Clinical guidelines development

Background:

  • Pediatric pulmonary vascular disease causes significant morbidity and mortality across numerous conditions.
  • Limited information exists on optimal diagnosis and evaluation strategies for pediatric pulmonary hypertension.
  • Pulmonary hypertension impacts diverse pediatric diseases, including congenital heart disease and sickle cell disease.

Purpose of the Study:

  • To address the need for improved diagnosis and evaluation of pediatric pulmonary hypertension.
  • To highlight key topics and recommendations from newly published clinical guidelines.
  • To provide guidance for practicing pediatricians and other healthcare professionals.

Main Methods:

  • Formation of a multidisciplinary expert task force supported by the American Heart Association and American Thoracic Society.
  • Review and synthesis of current evidence and expert clinical experience.
  • Publication of joint guidelines for the care of children with pulmonary hypertension.

Main Results:

  • Key topics and major recommendations for pediatric pulmonary hypertension care are presented.
  • Guidelines are based on the best available evidence and expert consensus.
  • The need for enhanced clinical research to improve long-term outcomes is emphasized.

Conclusions:

  • The published guidelines offer a critical resource for managing pediatric pulmonary hypertension.
  • Continued research is essential to advance the treatment and prognosis of pediatric pulmonary hypertension.
  • Multidisciplinary collaboration is key to addressing this complex pediatric condition.
Abstract

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
766
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
717
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
582
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
351
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
532